COMPLETED

Augmenting Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga Among Older Adults

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main purpose of this 12-week study is to see if a new combination of treatments can help older adults reduce benzodiazepine or related medication use. The treatment combination consists of 1) medical provider visits to gradually reduce the medication dose over 12 weeks, 2) acupuncture treatments, and 3) private yoga classes. Participants will be offered weekly visits for 12 weeks to receive combined treatments. Participants will be provided surveys before, during, and after the study to learn about their experience of the treatments. At the end of the study, participants will be invited to participate in a focus group to learn about their experience in the study.

Official Title

Augmenting Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga

Quick Facts

Study Start:2023-12-14
Study Completion:2025-05-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06197243

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 65 years and older
  2. * Taking benzodiazepines or related medications (i.e. zolpidem, zopiclone, eszopiclone, zaleplon) at least 4 times in the last month
  3. * English speaking
  4. * Ability to understand study procedures and to comply with them for the length of the study
  1. * Cognitive impairment
  2. * Drinking more than 3 alcoholic beverages per day
  3. * Substance abuse disorder
  4. * Uncontrolled psychiatric disorder, such as major depression or psychosis
  5. * Inability or unwillingness of individual or legal guardian.representative to give written informed consent.

Contacts and Locations

Principal Investigator

Gurjeet Birdee
PRINCIPAL_INVESTIGATOR
Vanderbilt University Medical Center

Study Locations (Sites)

Osher Center for Integrative Health at Vanderbilt
Nashville, Tennessee, 37203
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • Gurjeet Birdee, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-14
Study Completion Date2025-05-23

Study Record Updates

Study Start Date2023-12-14
Study Completion Date2025-05-23

Terms related to this study

Additional Relevant MeSH Terms

  • Anxiety
  • Insomnia
  • Benzodiazepine
  • Deprescription